The Commodification of the Right to Health by Nomani, Akif
1 
 
 
The Commodification of the Right to Health 
Akif  A. Nomani 
 
Within weeks of the first few confirmed deaths caused by the H1N1 flu, it was declared a global 
pandemic, and just as quickly in the U.S. and Canada, a vaccine was developed and distributed 
en masse.  The global crisis of the H1N1 flu brought to our attention the interesting relationship 
between globalization and the access to health care globally. Globalization, or the 
interconnectedness of the world’s markets, laws, and cultures, and its affect on health care, 
provides us a glimpse into the adverse relationship of health in developed and developing 
countries (Fidler 191). Unfortunately, developing countries, particularly those in Africa, entered 
the era of globalization with far worse health conditions than those in the developed world. As a 
result, in 1978 the World Health Organization (WHO) and UNICEF announced the Alma-Ata 
Declaration, which declared the goal of providing the human right to health for all by the year 
2000 (Aginam 619). However, the Alma-Ata Declaration has not been reached, and directly at 
fault for this failure are the processes of globalization.  This paper will argue that the failure of 
providing health care to those living in the developing world, especially in Africa, is because of 
the promotion of global governance modalities like the IMF, World Bank, and the WTO, which 
prevents developing countries from providing health care to its people for the advancement of 
the global capitalistic market and transnational corporations. 
 This paper will make this argument by examining the current health conditions of 
developing states. This will be followed by an analysis of the good governance agenda that 
Western nations believe will help improve health conditions around the world. I will then look at 
how the good governance agenda places greater importance on civil and political rights as 
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opposed to economic and social rights, such as the right to health. Next, I will analyze the impact 
of Structural Adjustment Programmes (SAPs) on the ability of developing nations to provide 
health care. I will also look at the WTO and its promotion of trade liberalization, and its impact 
on the quality of health care. As well, I will look at the WTO’s enforcement of patent protection, 
which causes new drugs to become too expensive for most people in developing countries to 
afford. Also, I will look at the how developing countries try to avoid paying high prices for 
essential drugs through the use of compulsory licenses. Finally, I will examine recent 
developments to improve access to health care, such as the Doha Declaration, which actually 
fails to provide real solutions to the issue of access to health care. However, I begin by 
discussing the development of ensuring health as a basic human right. 
 The proclamation that all humans have the fundamental human right to health was first 
declared by WHO in 1946, when it claimed that all humans should enjoy the highest standard of 
health, which was later expressed through programs like the Alma-Ata Declaration (Torres 105). 
This “second generation” human right is legally recognized by the majority of UN members 
under the International Covenant on Economic, Social, and Cultural Rights (ICESCR). 
Signatories of the ICESCR recognize that to ensure that all humans have the right to health, 
many measures are to be taken, but none more important than preventing and controlling 
diseases by assuring equal access to medical care for all (Torres 107).   
However, the widening gap in health conditions between developed and developing 
countries is becoming worse. In North America and Europe, people affected with infectious 
diseases like HIV/AIDS are living longer and healthier lives because of the accessibility of 
antiretroviral treatment (Geffen 497). However, infectious diseases kill over ten million people 
every year, and over 90% of those affected live in the developing world, where HIV/AIDS, 
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respiratory infections, malaria, and tuberculosis are leading causes of deaths (Hoen, 2002: 27). In 
fact, it is estimated that in the developing world, 8000 people die each day from HIV/AIDS 
(Hoen, 2002: 27). To alleviate the health gap, many non-governmental organizations (NGOs) 
have campaigned to increase the access to medical therapies in developing countries, so that they 
may treat infectious diseases, as is done in North America and Europe, where HIV/AIDS has 
become a managed chronic disease (Torres 105). Nonetheless, 95% of those in the developing 
world affected by infectious diseases are not able to afford medical treatment (Elliot). The 
question many are left asking is how could the developing world increase its access to health 
care to improve the health of its people?   
One solution offered was the good governance model. The good governance model 
suggests that the developing world, especially Sub- Saharan Africa, have been weakened in the 
international trading system because of strict economic regulations at the domestic level (Gathii 
1016). Africa’s policies of reliance on commodity exports, protectionist import policies, price 
controls and overall economic regulations, have led it to become marginalized in the global 
market (Fidler 202). Moreover, the lack of economic development is partly to blame for Africa’s 
inadequate access to health care (Fidler 202). However, the good governance agenda sets out to 
encourage developing countries to adopt policies as promoted by neo-liberal globalism.  Based 
on the “Washington Consensus”, the good governance agenda stipulates developing countries 
must liberalize their economies, by engaging in international trade, eliminating subsidies, 
increasing privatization, and protecting property rights (Abouharb 63). It is argued that this focus 
on economic development would reduce poverty in the developing world, which would in turn 
allow governments to invest more in their health care systems (Fidler 214).   
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The good governance agenda is promoted through global governance modalities like the 
International Monetary Fund (IMF), the World Bank, and the World Trade Organization (WTO).  
Since 1981, the IMF and World Bank, under the influence of Reagan and Thatcher, have 
promoted the Washington Consensus through structural adjustment programs (SAPs) (Abouharb 
15). The IMF and World Bank use SAPs to completely overhaul a country’s economy. In 
exchange for receiving loans to service its debts, a country must undertake a structural 
adjustment of its economy through a process that includes removing barriers to trade, 
deregulating the economy, reducing budget expenditures, and increasing foreign investment 
(Fidler 204).  The adoption of SAPs would improve the economic development of a developing 
country and assist its integration with the global market. A key element to this integration is the 
WTO. Established in 1995, the purpose of the WTO is to facilitate the liberalization and removal 
of barriers to trade by promoting the free movement of labour, capital, goods and services, along 
with the respect for intellectual property rights (Price 55). A general principle of the WTO is that 
members must accept all trade agreements as a package deal, must not discriminate between 
trading partners, and must harmonize trading policies with the global market (Mirza 93).  
However, the focus on economic liberalization has in fact restricted the role developing 
countries can play in increasing access to health care to its people. In terms of ideology, the good 
governance agenda is more inclined to place greater importance on civil and political rights over 
economic and social rights.  As argued earlier, the U.S. and its allies began promoting the good 
governance agenda of economic liberalization. Along with this promotion, the U.S. has 
supported the idea of political liberalization as expressed in the International Covenant on Civil 
and Political Rights (ICCPR), which promotes such rights like the right to self-determination, the 
right to a fair trial, freedom of expression and freedom of religion (Callaway 6). It is argued that 
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political freedom is necessary for citizens to have an opinion on what types of economic policies 
their governments should adopt (Gathii 1023).  Moreover, the political freedoms expressed in the 
ICCPR are referred to as negative rights because they require the government to refrain from 
interfering with the political liberties of its citizens, which in fact corresponds with the good 
governance agenda of eliminating government involvement in the economy (Gathii 1024).  
However, the right to health as promoted under the ICESCR is a positive right, which actually 
requires the state to take action in providing an adequate standard of living for its people 
(Callaway 7). In regards to the right to health, a government must ensure it provides its populace 
with an accessible and adequate health care system. Unfortunately, economic, social, and cultural 
rights are deemed inferior to civil and political rights by developed nations in their promotion of 
good governance. For example, the rights under the ICCPR are referred to as first generation 
rights, and thus are considered as being superior to second generation rights under ICESCR, 
including the right to health (Aginam 614). Consequently, the IMF and World Bank have heavily 
promoted this false idea of subordination.  
The IMF and World Bank have argued that SAPs have in fact stabilized the economies of 
developing nations, which has allowed them to repay their debt (Aginam 621).  However, there 
is a great cost to the economic restructuring these countries are required to undertake. The 
conditions promoted through SAPs forces developing countries to drastically reduce 
expenditures in the health care sector in return for receiving loans (Fidler 205). For example, 
developing states undertake certain types of projects deemed necessary for economic growth, 
such as the building of dams, roads, railways, and commercial farming land (Callaway 248). 
Inevitably, social programs like health care are sacrificed. To reduce government expenses, 
developing countries would eliminate subsidies in the health care sector, and would instead 
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impose user fees, even though most patients are unable to afford it (Fidler 205). A consequence 
of eliminating subsidies is a dramatic reduction in health care quality and access (Fidler 205). In 
fact, many developing countries that have adopted SAPs, have seen increases in infectious 
diseases. For instance, Costa Rica implemented SAPs in 1981 and reduced its investment in the 
health care sector.  As a result, in 1985 the Ministry of Health reported an increase in infectious 
diseases (Abouharb 139). Economist Michel Chossudovsky refers to this development as a form 
of “market colonialism”, in reference to a new form of economic domination (Aginam 621). The 
IMF and World Bank are more concerned about financial profits for banks and transnational 
corporations (TNCs) located in developed states than social development of developing states 
(Callaway 249). Unfortunately, developing states are pressured into adopting policies that will 
attract foreign investment and trade, and to do so they must sacrifice social and economic 
priorities, like health care, which should be more of a concern than increasing the profits of 
external agents and satisfying the global market (Fidler 206).  
As mentioned earlier, the WTO plays a central role in facilitating the foreign investment 
and trade that is promoted by the IMF and World Bank under the guise of “good governance”.  
The General Agreement on Trade in Services (GATS) is an important international agreement 
that all WTO members must follow in their effort to liberalize international trade. GATS is an 
international agreement that stipulates WTO members to eliminate any barriers to trade, and is 
not restricted to border controls like tariffs, but also targets any laws, requirements, practices, 
procedures, or “any other form” that regulates trade in goods and services (Price 55). In fact, one 
of the consequences of this trade liberalization is that developing countries see a fall in budget 
revenue because of the loss of revenue from trade taxes, which essentially accounts for a loss of 
one-third of all budget revenue in most countries (Abouharb 142). As a result, in an attempt to 
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repay budget deficits, these counties must cut back spending in public services like health care 
(Abouharb 142). Consequently, health care policies are reformed to accommodate the private 
sector.  
Yet, as restrictive as these measures have been in providing health care to people of 
developing countries, none are more detrimental than the agreement on Trade-Related Aspects of 
Intellectual Property (TRIPS). With over 90% of those affected by infectious diseases living in 
the developing world, the cost of receiving therapy is far too expensive because of contrary 
restrictions imposed by WTO. TRIPS, which is managed by the WTO, does not advance trade 
liberalization, but in fact restricts trade in the pharmaceutical industry (Elliot). TRIPS 
monopolizes the pharmaceutical industry by regulating the standards of the industry in regards to 
patent protection. Under TRIPS, patents for inventions, including both the product and the 
process, is to be respected for a minimum of twenty years (Sykes 3). In terms of the 
pharmaceutical industry, article 28 of TRIPS awards to a corporation the exclusive right to make, 
use, and sale its patented product or process (Sykes 3).  Moreover, signatories to TRIPS agree to 
the principles of “national treatment” and “most favoured nation treatment”, which means that it 
is illegal for a country to discriminate between local or foreign companies or countries (Mirza 
93). Not surprisingly, 97% of the patents are held by individuals and companies belonging to the 
developed world (Hoen, 2002: 37).  
Critics of TRIPS argue that these patent protections are for the sole purpose of securing 
profits for corporations. While not refuted, pharmaceutical executives contend that seeking 
profits can be justified. They claim that the cost of investing in research and development of new 
medicines is extremely expensive (Elliot). Thus, these companies need strong patent protection 
to ensure a greater return on their investment. However, this argument is weak for several 
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reasons. Firstly, much of the costs these companies are “burdened” with are financed by public 
research funds, and a portion of it is used on advertising new drugs (Elliot). Also, pharmaceutical 
companies do not disclose the actual costs of research and development (R&D), so information 
that is reported can be unreliable. For example, various reports state that the cost of R&D on a 
single drug can vary from $1 to $200 million (Hoen, 1999: 90). On the other hand, the profits 
these drugs generate for companies are much greater than any estimates of the cost of R&D. For 
example, pharmaceutical company Glaxco Wellcome made $589 million in one year on one 
AIDS drug that will be protected by patents and sold for over twenty years (Elliot).  
Nevertheless, the impact that TRIPS has had on the cost of purchasing drugs cannot be 
disputed. For example, 150mg of the HIV drug fluconazole costs $55 in India, where the drug is 
not patented. However, the same drug costs $697 in Malaysia, $703 in Indonesia, and $817 in the 
Philippines, where the drug is patented (Sykes 1). Moreover, the HIV treatment AZT costs $48 
per month in India, but costs $239 per month in the U.S., where it is patent protected (Sykes 1). 
While most people in the U.S. can afford to pay $239 per month, such prices far exceed what 
most people in the developing world can afford to pay. As a result, most people would have no 
option but to wait twenty years until the patent has expired and generic drugs can be produced 
(Mirza 94). In fact, WHO in 1985 reported that 75% of the world’s population living in 
developing countries consumed only 11% of available drugs (Mirza 93). So while the U.S. 
makes up 33% of the global market share in pharmaceuticals, Africa accounts for only 1.8% 
(Mirza 93). However, since these companies are seeking a profit, most tend to develop and 
market drugs that are intended for developed countries (Elliot). The casualty of this capitalistic 
focus of health care is that these companies eventually discontinue the production of some 
essential drugs needed in the developing world. For instance, Merrell Dow discontinued the 
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production of the drug DMFO in the early 1990s for a lack of “commercial opportunities”, which 
is used to treat the deadly disease “sleeping sickness” that affects 30,000 people in Africa, 
(Hoen, 1999: 88). In fact, between 1975 and 1997, 1223 new drugs were produced, out of which 
only thirteen treated tropical diseases (Mirza 95). On a side note, of those thirteen, only four 
were directly developed through research. Yet, as stated by the European Directorate General for 
Trade, “no priority should be given to health over intellectual property considerations” (Hoen, 
2002: 36).  
Nonetheless, governments of developing countries are becoming increasingly assertive in 
criticizing the structure of the trading system and are discovering solutions through legal 
channels. One such solution is the use of compulsory licensing, which is outlined in Article 31 of 
TRIPS that states a country is allowed to issue licenses to local companies to manufacture 
generic versions of expensive and patented drugs, but with the condition that a small royalty 
must be paid to the patent holder (Fidler 211). Nevertheless, these generic drugs remain much 
more affordable for people in developing countries to purchase than protected drugs.  
However, many feel compulsory licensing as stated in TRIPS is ambiguous and so many 
developing countries are reluctant to use it in fear that developed states or pharmaceutical 
companies will take action against its use (Geffen 498). As was the case in South Africa, in 
which the government was pressured by the U.S. to not continue its use of compulsory licenses 
for the production of HIV/AIDS drugs (Fidler 211). In 1998, when the South African 
government ignored the demands, dozens of pharmaceutical companies and organizations 
alleged it had violated TRIPS by issuing compulsory licenses and took the government to court 
(Hoen, 2002: 30). In fact, the U.S. and the European Commission (EU) placed trade sanctions 
against South Africa. However, increasing public pressure and protests forced the U.S. and EU to 
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drop their demands, which was followed by the pharmaceutical companies dropping their case 
(Hoen, 2002: 30).  
Nevertheless, developing countries believed certain clarifications needed to be made in 
regards to TRIPS and compulsory licenses, so that cases like South Africa would not be 
repeated.  Thus, during the fourth WTO ministerial meetings in Doha, a legal declaration was 
agreed upon. The 2001 Declaration on the TRIPS Agreement and Public Health (Doha 
Declaration) clarified that TRIPS should not interfere with a country’s ability to provide access 
to health care to its public, especially those most affected by infectious diseases like HIV/AIDS 
(Sykes 5). Moreover, each government has the right to issue compulsory licenses, especially in 
cases of national emergency or other public health crises that are solely determined by that 
government only (Sykes 5).  
Unfortunately, the Doha declaration has severe shortfalls. Critics have even questioned 
the process that was taken to reach the declaration. Firstly, Qatar is a monarchy and thus it was 
able to limit public protests (Bello 275). As made clear in Seattle and South Africa, public 
protests can play an important role in political discussions. However, Qatar decided to authorize 
the WTO to grant entry visas, which allowed it to restrict the amount of NGOs accepted into the 
country (Bello 275). Moreover, reports state that Western nations used unfair tactics to force 
compliance on the part of developing states. For example, the U.S. notified the representatives of 
Haiti and the Dominican Republic that if they did not comply with U.S. demands, it would 
abandon any favourable trade agreements it has with both countries (Bello 275). On the other 
hand, the EU offered preferential trade agreements for agricultural commodities to states from 
Africa and the Caribbean, in return for approving the final declaration. Lastly, Nigeria was 
offered a favourable economic and military aid package by the U.S., in return for abandoning its 
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position of denouncing the declaration. As a result of these tactics, the Doha Declaration was 
signed by all members despite its clear weaknesses.  
For one, many developing states wanted some additions to TRIPS. They wanted to clarify 
that they have the right to grant compulsory licenses to foreign states or companies because 
many countries do not have the technical ability to produce drugs (Sykes 5). However, no such 
clarifications were made, and so most developing countries are only able to use compulsory 
licenses for domestic productions. Moreover, the claim that the TRIPS agreement must not 
interfere with measures to protect public health is simply a political statement and is not legally 
binding on members (Bello 274). Thus, there are no legal stipulations in the Doha Declaration 
for developed states or pharmaceutical companies to follow, allowing them in the future to take 
developing states to court over any disagreements (Bello 274). Unfortunately, the Doha 
Declaration does not offer any substantial changes or solutions to TRIPS, but only preserves the 
misguided principle that profits come before health.  
In conclusion, this paper argued that through global governance modalities like the IMF, 
World Bank, and the WTO, the ability of providing the human right to health is disregarded by 
developed countries in favour for market considerations or simply profit. This paper made this 
argument by examining the effects of the good governance agenda, the importance placed on 
civil and political rights, the promotion of SAPs, the patent regulations enforced by the WTO, 
and the questionable impact of the Doha Declaration. As made clear above, viable solutions are 
hard to come by when there are such clear oppositions to reaching one. However, what is clear is 
that pressure from the public makes a difference. Thus, there needs to be a continued effort to 
protest, so that we may ensure that public health will never be sacrificed for private profit.   
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